JP2017508744A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017508744A5 JP2017508744A5 JP2016555329A JP2016555329A JP2017508744A5 JP 2017508744 A5 JP2017508744 A5 JP 2017508744A5 JP 2016555329 A JP2016555329 A JP 2016555329A JP 2016555329 A JP2016555329 A JP 2016555329A JP 2017508744 A5 JP2017508744 A5 JP 2017508744A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- inhibitor
- composition according
- activity
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 21
- 101150096839 Fcmr gene Proteins 0.000 claims 14
- 230000000694 effects Effects 0.000 claims 11
- 239000003112 inhibitor Substances 0.000 claims 10
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 5
- 239000012275 CTLA-4 inhibitor Substances 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 239000012270 PD-1 inhibitor Substances 0.000 claims 4
- 239000012668 PD-1-inhibitor Substances 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 4
- 238000012790 confirmation Methods 0.000 claims 4
- 229940121655 pd-1 inhibitor Drugs 0.000 claims 4
- 230000002708 enhancing effect Effects 0.000 claims 3
- 210000004698 lymphocyte Anatomy 0.000 claims 3
- 102100032814 ATP-dependent zinc metalloprotease YME1L1 Human genes 0.000 claims 2
- 101800000795 Proadrenomedullin N-20 terminal peptide Proteins 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- PIRWNASAJNPKHT-SHZATDIYSA-N pamp Chemical compound C([C@@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)N)C(C)C)C1=CC=CC=C1 PIRWNASAJNPKHT-SHZATDIYSA-N 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 101100463133 Caenorhabditis elegans pdl-1 gene Proteins 0.000 claims 1
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims 1
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 claims 1
- 229940125563 LAG3 inhibitor Drugs 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461949927P | 2014-03-07 | 2014-03-07 | |
| US61/949,927 | 2014-03-07 | ||
| PCT/IB2015/001033 WO2015132675A2 (en) | 2014-03-07 | 2015-03-06 | Methods and compositions for modifying the immune response |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019106087A Division JP2019147839A (ja) | 2014-03-07 | 2019-06-06 | 免疫応答を調節するための方法及び組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017508744A JP2017508744A (ja) | 2017-03-30 |
| JP2017508744A5 true JP2017508744A5 (enExample) | 2018-05-31 |
| JP6538707B2 JP6538707B2 (ja) | 2019-07-03 |
Family
ID=54016312
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016555329A Expired - Fee Related JP6538707B2 (ja) | 2014-03-07 | 2015-03-06 | 免疫応答を調節するための方法及び組成物 |
| JP2019106087A Pending JP2019147839A (ja) | 2014-03-07 | 2019-06-06 | 免疫応答を調節するための方法及び組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019106087A Pending JP2019147839A (ja) | 2014-03-07 | 2019-06-06 | 免疫応答を調節するための方法及び組成物 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US20150250853A1 (enExample) |
| EP (2) | EP3616718A1 (enExample) |
| JP (2) | JP6538707B2 (enExample) |
| KR (1) | KR20160127817A (enExample) |
| AU (1) | AU2015225867B2 (enExample) |
| CA (3) | CA2941693A1 (enExample) |
| IL (1) | IL247614B (enExample) |
| WO (3) | WO2015132675A2 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10441654B2 (en) | 2014-01-24 | 2019-10-15 | Children's Hospital Of Eastern Ontario Research Institute Inc. | SMC combination therapy for the treatment of cancer |
| WO2015132675A2 (en) | 2014-03-07 | 2015-09-11 | University Health Network | Methods and compositions for modifying the immune response |
| ES2690420T3 (es) | 2015-05-28 | 2018-11-20 | Universität Zu Köln | Receptor de antígeno quimérico anti-toso y su uso |
| IL272697B2 (en) | 2017-08-18 | 2023-12-01 | Adastra Pharmaceuticals Inc | A polymorphic form of TG02 |
| SG11202107317WA (en) | 2019-01-18 | 2021-08-30 | Dracen Pharmaceuticals Inc | Combinaton therapy with a don prodrug and an immune checkpoint inhibitor |
| TWI857009B (zh) * | 2019-02-15 | 2024-10-01 | 大學健康網絡 | Ｆｃｍｒ結合分子及其用途 |
| WO2020219721A1 (en) * | 2019-04-23 | 2020-10-29 | The Broad Institute, Inc. | Compositions and methods characterizing metastasis |
| US20220304984A1 (en) | 2019-06-12 | 2022-09-29 | Vanderbilt University | Amino acid transport inhibitors and the uses thereof |
| WO2020252336A1 (en) | 2019-06-12 | 2020-12-17 | Vanderbilt University | Dibenzylamines as amino acid transport inhibitors |
| BR112021026334A2 (pt) | 2019-06-27 | 2022-05-10 | Medstar Health | Macrófagos ativados por hdac6, composições, e usos dos mesmos |
| CA3138560A1 (en) | 2019-07-16 | 2021-01-21 | Shaomeng Wang | Imidazopyrimidines as eed inhibitors and the use thereof |
| JP7196798B2 (ja) | 2019-08-09 | 2022-12-27 | 株式会社Soken | 超音波センサ |
| CA3151824A1 (en) | 2019-08-27 | 2021-03-04 | The Regents Of The University Of Michigan | Cereblon e3 ligase inhibitors |
| CA3176606A1 (en) * | 2020-03-26 | 2021-09-30 | Cureimmune Therapeutics Inc. | Anti-pd-1 antibodies and methods of use |
| US20240166647A1 (en) | 2021-03-03 | 2024-05-23 | The Regents Of The University Of Michigan | Cereblon Ligands |
| WO2025151487A2 (en) | 2024-01-08 | 2025-07-17 | Regents Of The University Of Michigan | Small-molecule inhibitors of adar1 |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| EP1186660A3 (fr) | 1985-03-30 | 2002-03-20 | KAUFFMAN, Stuart A. | Procédé d'obtension d'ADN, ARN, peptides, polypeptides ou protéines, par une technique de recombination d'ADN |
| DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
| US5618920A (en) | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
| WO1987005330A1 (en) | 1986-03-07 | 1987-09-11 | Michel Louis Eugene Bergh | Method for enhancing glycoprotein stability |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| US4704692A (en) | 1986-09-02 | 1987-11-03 | Ladner Robert C | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
| US5763192A (en) | 1986-11-20 | 1998-06-09 | Ixsys, Incorporated | Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique |
| EP0832981A1 (en) | 1987-02-17 | 1998-04-01 | Pharming B.V. | DNA sequences to target proteins to the mammary gland for efficient secretion |
| US5229490A (en) | 1987-05-06 | 1993-07-20 | The Rockefeller University | Multiple antigen peptide system |
| US4873316A (en) | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5686073A (en) | 1990-05-23 | 1997-11-11 | The University Of Iowa Research Foundation | Polyclonal and monoclonal antibodies against a 43 KDA dystrophin associated protein |
| CA2090126C (en) | 1990-08-02 | 2002-10-22 | John W. Schrader | Methods for the production of proteins with a desired function |
| US6797492B2 (en) | 1991-05-17 | 2004-09-28 | Merck & Co., Inc. | Method for reducing the immunogenicity of antibody variable domains |
| EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
| DK0608261T3 (da) | 1991-09-13 | 2003-03-17 | Chiron Corp | Sammensætninger med immunreaktivt hepatitis C virus polypeptid |
| DK0617706T3 (da) | 1991-11-25 | 2001-11-12 | Enzon Inc | Multivalente antigenbindende proteiner |
| ATE249840T1 (de) | 1991-12-13 | 2003-10-15 | Xoma Corp | Verfahren und materialien zur herstellung von modifizierten variablen antikörperdomänen und ihre therapeutische verwendung |
| US5455338A (en) | 1993-11-05 | 1995-10-03 | Zymogenetics, Inc. | DNA encoding novel human kunitz-type inhibitors and methods relating thereto |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| US5714352A (en) | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
| US6709659B1 (en) | 1996-08-02 | 2004-03-23 | Zymogenetics, Inc. | Antibodies that bind testis-specific insulin homolog polypeptides |
| US6727350B2 (en) | 1997-11-17 | 2004-04-27 | The Board Of Trustees Of The Leland Stanford Junior University | Toso |
| US6555314B1 (en) * | 1998-03-30 | 2003-04-29 | Rigel Pharmaceuticals, Inc. | Toso as a target for drug screening |
| PT2180007E (pt) | 1998-04-20 | 2013-11-25 | Roche Glycart Ag | Engenharia de glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos |
| US6322788B1 (en) | 1998-08-20 | 2001-11-27 | Stanley Arthur Kim | Anti-bacterial antibodies and methods of use |
| US6632926B1 (en) | 1998-11-18 | 2003-10-14 | Genentech, Inc. | Antibody variants |
| EP2275540B1 (en) | 1999-04-09 | 2016-03-23 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| US6939545B2 (en) | 1999-04-28 | 2005-09-06 | Genetics Institute, Llc | Composition and method for treating inflammatory disorders |
| JP4668498B2 (ja) | 1999-10-19 | 2011-04-13 | 協和発酵キリン株式会社 | ポリペプチドの製造方法 |
| CA2419979A1 (en) | 2000-09-08 | 2002-03-14 | Schering Corporation | Mammalian genes; related reagents and methods |
| KR100877676B1 (ko) | 2000-10-06 | 2009-01-09 | 교와 핫꼬 기린 가부시키가이샤 | 항체 조성물을 생산하는 세포 |
| WO2002030954A1 (en) | 2000-10-06 | 2002-04-18 | Kyowa Hakko Kogyo Co., Ltd. | Method of purifying antibody |
| US20020127557A1 (en) * | 2001-03-09 | 2002-09-12 | Ruoying Tan | Method for identification of cDNAs encoding signal peptides |
| ATE406094T1 (de) * | 2001-03-28 | 2008-09-15 | Dana Farber Cancer Inst Inc | Identifizierung und charakterisierung von genen |
| EP1391213A1 (en) | 2002-08-21 | 2004-02-25 | Boehringer Ingelheim International GmbH | Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents |
| US7610156B2 (en) | 2003-03-31 | 2009-10-27 | Xencor, Inc. | Methods for rational pegylation of proteins |
| US7119179B1 (en) | 2005-03-21 | 2006-10-10 | Los Alamos National Security, Llc | Preparation of high nitrogen compound and materials therefrom |
| MX2010014280A (es) * | 2008-06-26 | 2011-05-23 | Dana Farber Cancer Inst Inc | Distintivos y determinantes asociados con metástasis y método para utilizarlos. |
| US20110306655A1 (en) * | 2009-02-19 | 2011-12-15 | Richard Antonius Jozef Janssen | Methods for identifying and compounds useful for the diagnosis and treatment of diseases involving inflammation |
| US10817851B2 (en) | 2009-12-23 | 2020-10-27 | Aristocrat Technologies Australia Pty Limited | System and method for cashless gaming |
| CA2867444C (en) * | 2012-03-16 | 2021-04-13 | University Health Network | Compositions containing soluble toso protein and uses thereof |
| EA038702B1 (ru) * | 2012-03-30 | 2021-10-07 | Иммьюн Дизайн Корп. | Лентивирусные векторные частицы, имеющие улучшенную эффективность трансдукции клеток, экспрессирующих dc-sign |
| US20140294792A1 (en) * | 2013-02-22 | 2014-10-02 | The Board Of Trustees Of The University Of Illinois | T-REG Cell Expansion |
| WO2015132675A2 (en) | 2014-03-07 | 2015-09-11 | University Health Network | Methods and compositions for modifying the immune response |
-
2015
- 2015-03-06 WO PCT/IB2015/001033 patent/WO2015132675A2/en not_active Ceased
- 2015-03-06 WO PCT/IB2015/000996 patent/WO2015132672A2/en not_active Ceased
- 2015-03-06 EP EP19170244.8A patent/EP3616718A1/en not_active Withdrawn
- 2015-03-06 AU AU2015225867A patent/AU2015225867B2/en not_active Ceased
- 2015-03-06 KR KR1020167027415A patent/KR20160127817A/ko not_active Ceased
- 2015-03-06 CA CA2941693A patent/CA2941693A1/en not_active Abandoned
- 2015-03-06 EP EP15757961.6A patent/EP3113798B1/en active Active
- 2015-03-06 US US14/640,318 patent/US20150250853A1/en not_active Abandoned
- 2015-03-06 US US14/641,023 patent/US20150252434A1/en not_active Abandoned
- 2015-03-06 JP JP2016555329A patent/JP6538707B2/ja not_active Expired - Fee Related
- 2015-03-06 CA CA2941697A patent/CA2941697A1/en not_active Abandoned
- 2015-03-07 US US14/641,358 patent/US10533222B2/en not_active Expired - Fee Related
- 2015-03-07 CA CA2941691A patent/CA2941691A1/en not_active Abandoned
- 2015-03-07 WO PCT/IB2015/000912 patent/WO2015132670A2/en not_active Ceased
-
2016
- 2016-09-04 IL IL247614A patent/IL247614B/en active IP Right Grant
-
2019
- 2019-06-06 JP JP2019106087A patent/JP2019147839A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017508744A5 (enExample) | ||
| Dyck et al. | Immune checkpoints and their inhibition in cancer and infectious diseases | |
| PE20190911A1 (es) | Composiciones y anticuerpos anti-lag-3 | |
| RU2016107426A (ru) | Комбинирование агонистов cd27 и ингибирование иммунных контрольных точек для стимуляции иммунитета | |
| Park et al. | PD-1 upregulated on regulatory T cells during chronic virus infection enhances the suppression of CD8+ T cell immune response via the interaction with PD-L1 expressed on CD8+ T cells | |
| EA201792573A1 (ru) | Триспецифические связанные белки и способы их применения | |
| PH12018501220A1 (en) | Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof | |
| JP2019508444A5 (enExample) | ||
| JP2017534633A5 (enExample) | ||
| JP2018508483A5 (enExample) | ||
| JP2016531907A5 (enExample) | ||
| JP2018515474A5 (enExample) | ||
| MX2018010824A (es) | Proteinas de union inducibles y metodos de uso. | |
| JP2017524348A5 (enExample) | ||
| HRP20190881T1 (hr) | Kombinacijska terapija s hijaluronan-razgrađujućim enzimom i inhibitorom imunološke kontrolne točke | |
| MY200849A (en) | Anti-Icos Agonist Antibodies and uses Thereof | |
| JP2018520679A5 (enExample) | ||
| SG10201805411YA (en) | Chimeric antigen receptors | |
| JP2019504892A5 (enExample) | ||
| HK1254861A1 (zh) | 抗lag3抗体及其用途 | |
| RU2021114500A (ru) | НАПРАВЛЕННОЕ ИНГИБИРОВАНИЕ TGFβ | |
| EA201690567A1 (ru) | Антитела против pd1 и их применение в качестве терапевтических и диагностических средств | |
| JP2018514550A5 (enExample) | ||
| Lynch et al. | Adoptive transfer of murine T cells expressing a chimeric‐PD 1‐Dap10 receptor as an immunotherapy for lymphoma | |
| CN104245736A (zh) | 抗人死亡受体5胞外区的人源化单克隆抗体 |